Publication
AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.
Jessica A Pollard, Todd A Alonzo, Robert B Gerbing, Matthew Kutny, Betsy Hirsch, Gordana Raca, Kasey Leger, Jennifer Wilkes, Reena Pabari, Aman Wadhwa, Zachary Graff, Samir Kahwash, Karen Chisholm, Joseph Chewning, John Horan, Richard Aplenc, Andrew Place, Sarah K Tasian, Katherine Tarlock, Sarah Menig, Olga Militano, Bonnie Ky, Chad Hudson, Michael R Loken, Andrew Menssen, Lisa Eidenschink Brodersen, Soheil Meshinchi, Edward Anders Kolb, Todd M Cooper
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: The Children's Oncology Group phase III clinical trial AAML1831 (ClinicalTrials.gov identifier: NCT04293562) evaluated liposomal daunorubicin and cytarabine (CPX-351) versus standard daunorubicin/cytarabine (DA) induction therapy in children and young adults with newly diagnosed AML. We…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04293562registry_reference1.00
Registered trialsNCT04293562
Curated evidence
Evidence citing this paper (0)
Data not yet available